XYNTHA temporarily replaces the missing clotting factor VIII that is needed for effective hemostasis.
The activated partial thromboplastin time (aPTT) is prolonged in patients with hemophilia. Determination of aPTT is a conventional in vitro assay for biological activity of factor VIII. Treatment with XYNTHA normalizes the aPTT over the effective dosing period.
The pharmacokinetic parameters of XYNTHA in 30 PTPs 12 to 60 years old, who received a single infusion of 50 IU/kg XYNTHA are summarized in Table 3.
In addition, 25 of the same subjects later received a single infusion of 50 IU/kg of XYNTHA for a 6-month follow-up pharmacokinetic study. The parameters were comparable between baseline and 6 months, indicating no time-dependent changes in the pharmacokinetics of XYNTHA.
In a separate study, 8 of 30 subjects at least 12 years old with hemophilia A undergoing elective major surgery received a single 50 IU/kg infusion of XYNTHA. The pharmacokinetic parameters in these subjects are also summarized in Table 3.
| Parameter | Initial Visit (n = 30) | Month 6 (n = 25) | Pre-surgery (n=8) |
|---|---|---|---|
| Abbreviations: AUC∞ = area under the plasma concentration-time curve from zero to infinity; Cmax = peak concentration; t1/2 = plasma elimination half-life; CL = clearance; n = number of subjects; SD = standard deviation; Vss = volume of distribution at steady-state. | |||
| |||
| Cmax (IU/mL) | 1.08 ± 0.22 | 1.24 ± 0.42 | 1.08 ± 0.24 |
| AUC∞ (IU∙hr/mL) | 13.5 ± 5.6 | 15.0 ± 7.5 | 16.0 ± 5.2 |
| t1/2 (hr) | 11.2 ± 5.0 | 11.8 ± 6.2* | 16.7 ± 5.4 |
| CL (mL/hr/kg) | 4.51 ± 2.23 | 4.04 ± 1.87 | 3.48 ± 1.25 |
| Vss (mL/kg) | 66.1 ± 33.0 | 67.4 ± 32.6 | 69.0 ± 20.1 |
| Recovery (IU/dL per IU/kg) | 2.15 ± 0.44 | 2.47 ± 0.84 | 2.17 ± 0.47 |
Table 4 shows the pharmacokinetic parameters of nine children; four aged 14 or 15 years of age, who are also included in the summary for the adults above, along with five children aged 3.7–5.8 years after single 50 IU/kg doses of XYNTHA. Compared to adults, the half-life of XYNTHA is shorter in children and the clearance (based on per kg body weight) is approximately 40% higher in children.
| Parameter | Young Children (n = 5) | Adolescents (n = 4) |
|---|---|---|
| Abbreviations: AUC∞ = area under the plasma concentration-time curve from zero to infinity; Cmax = peak concentration; t1/2 = plasma elimination half-life; CL = clearance; n = number of subjects; SD = standard deviation; Vss = volume of distribution at steady-state. | ||
| Age (min-max, yr) | 3.7–5.8 | 14–15 |
| Cmax (IU/mL) | 0.78 ± 0.34 | 0.97 ± 0.21 |
| AUC∞ (IU∙hr/mL) | 12.2 ± 6.50 | 8.5 ± 4.0 |
| t1/2 (hr) | 8.3 ± 2.7 | 6.9 ± 2.4 |
| CL (mL/hr/kg) | 6.29 ± 4.87 | 6.62 ± 2.16 |
| Vss (mL/kg) | 66.9 ± 55.6 | 67.1 ± 13.6 |
| Recovery (IU/dL per IU/kg) | 1.52 ± 0.69 | 1.95 ± 0.41 |
XYNTHA temporarily replaces the missing clotting factor VIII that is needed for effective hemostasis.
The activated partial thromboplastin time (aPTT) is prolonged in patients with hemophilia. Determination of aPTT is a conventional in vitro assay for biological activity of factor VIII. Treatment with XYNTHA normalizes the aPTT over the effective dosing period.
The pharmacokinetic parameters of XYNTHA in 30 PTPs 12 to 60 years old, who received a single infusion of 50 IU/kg XYNTHA are summarized in Table 3.
In addition, 25 of the same subjects later received a single infusion of 50 IU/kg of XYNTHA for a 6-month follow-up pharmacokinetic study. The parameters were comparable between baseline and 6 months, indicating no time-dependent changes in the pharmacokinetics of XYNTHA.
In a separate study, 8 of 30 subjects at least 12 years old with hemophilia A undergoing elective major surgery received a single 50 IU/kg infusion of XYNTHA. The pharmacokinetic parameters in these subjects are also summarized in Table 3.
| Parameter | Initial Visit (n = 30) | Month 6 (n = 25) | Pre-surgery (n=8) |
|---|---|---|---|
| Abbreviations: AUC∞ = area under the plasma concentration-time curve from zero to infinity; Cmax = peak concentration; t1/2 = plasma elimination half-life; CL = clearance; n = number of subjects; SD = standard deviation; Vss = volume of distribution at steady-state. | |||
| |||
| Cmax (IU/mL) | 1.08 ± 0.22 | 1.24 ± 0.42 | 1.08 ± 0.24 |
| AUC∞ (IU∙hr/mL) | 13.5 ± 5.6 | 15.0 ± 7.5 | 16.0 ± 5.2 |
| t1/2 (hr) | 11.2 ± 5.0 | 11.8 ± 6.2* | 16.7 ± 5.4 |
| CL (mL/hr/kg) | 4.51 ± 2.23 | 4.04 ± 1.87 | 3.48 ± 1.25 |
| Vss (mL/kg) | 66.1 ± 33.0 | 67.4 ± 32.6 | 69.0 ± 20.1 |
| Recovery (IU/dL per IU/kg) | 2.15 ± 0.44 | 2.47 ± 0.84 | 2.17 ± 0.47 |
Table 4 shows the pharmacokinetic parameters of nine children; four aged 14 or 15 years of age, who are also included in the summary for the adults above, along with five children aged 3.7–5.8 years after single 50 IU/kg doses of XYNTHA. Compared to adults, the half-life of XYNTHA is shorter in children and the clearance (based on per kg body weight) is approximately 40% higher in children.
| Parameter | Young Children (n = 5) | Adolescents (n = 4) |
|---|---|---|
| Abbreviations: AUC∞ = area under the plasma concentration-time curve from zero to infinity; Cmax = peak concentration; t1/2 = plasma elimination half-life; CL = clearance; n = number of subjects; SD = standard deviation; Vss = volume of distribution at steady-state. | ||
| Age (min-max, yr) | 3.7–5.8 | 14–15 |
| Cmax (IU/mL) | 0.78 ± 0.34 | 0.97 ± 0.21 |
| AUC∞ (IU∙hr/mL) | 12.2 ± 6.50 | 8.5 ± 4.0 |
| t1/2 (hr) | 8.3 ± 2.7 | 6.9 ± 2.4 |
| CL (mL/hr/kg) | 6.29 ± 4.87 | 6.62 ± 2.16 |
| Vss (mL/kg) | 66.9 ± 55.6 | 67.1 ± 13.6 |
| Recovery (IU/dL per IU/kg) | 1.52 ± 0.69 | 1.95 ± 0.41 |
{{section_body_html_patient}}
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.